Veregen

Veregen is a brand name of sinecatechins topical, approved by the FDA in the following formulation(s):

VEREGEN (sinecatechins - ointment; topical)

• 
  Manufacturer: MEDIGENE AG
  
  Approval date: October 31, 2006
  
  Strength(s): 15% ^[RLD]

Has a generic version of Veregen been approved?

No. There is currently no therapeutically equivalent version of Veregen available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Veregen. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Composition for treating Condyloma acuminata
  Patent 5,795,911
  Issued: August 18, 1998
  Inventor(s): Cheng; Shu Jun & Wang; De Chang & Hara; Yukihiko
  Assignee(s): Cancer Institute (Hospital), Chinese Academy of Medical Sciences
  Mitsui Norin Co., Ltd.
  A composition for a treatment of HPV-infected Condyloma acuminata which comprises containing tea catechin as a main component. This medication has no danger of side-effects and may be easily applied to or inserted in the infected area by the patient themselves.
  
  Patent expiration dates:
  
  
  • October 31, 2020
    
    ✓ 
    Patent use: TREATMENT OF GENITAL WARTS
  
  



• 
  Method for treating hyperplasia
  Patent 5,968,973
  Issued: October 19, 1999
  Inventor(s): Cheng; Shu Jun & Wang; De Chang & Hara; Yukihiko
  Assignee(s): Cancer Institute (Hospital), Chinese Academy of Medical Sciences
  Mitsui Norin Co., Ltd.
  A method for a treatment of hyperplasia caused by papilloma virus, such as for treating Condyloma acuminata which comprises administering tea catechin. Tea catechins do not involve the risk of side-effects and may be easily applied to or inserted in the infected area by the patients themselves.
  
  Patent expiration dates:
  
  
  • April 10, 2017
    
    ✓ 
    Patent use: TREATMENT OF GENITAL WARTS
  
  



• 
  Medicament for the treatment of viral skin and tumour diseases
  Patent 7,858,662
  Issued: December 28, 2010
  Inventor(s): Chang; Yunik & Lathrop; Robert & Böhm; Erwin & Gander-Meisterernst; Irene & Greger; Regina & Holldack; Johanna & Moebius; Ulrich
  Assignee(s): MediGene AG
  The invention relates to a medicament containing a compound of general formula (1), where R1=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C11-C21 alkyl, alkylene or alkynyl group, preferably a C11-C15 alkyl, alkylene or alkynyl group, particularly a C11-C13 alkyl, alkylene or alkynyl group, most preferably a C13 alkyl group, R2=independently, a straight or branched C1-C8 alkyl, alkylene or alkynyl group, preferably a C1-C6 alkyl, alkylene or alkynyl group, in particular a C2-C4 alkyl, alkylene or alkynyl group, most preferably a C3 alkyl group, a —[CH2—(CH2)m—O]nH group with n=1 to 10, preferably n=1 to 5, m=1 to 5, preferably m=1 to 3, a —CH2—[CH—(OH)]p[CH2—(R3)]— group, where R3=independent H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/or tumor diseases, in particular caused by human papilloma virus (HPV) and/or herpes viruses and a topically acting medicament formulation and the use thereof.
  
  Patent expiration dates:
  
  
  • October 2, 2026
    
    ✓ 
    Patent use: TREATMENT OF GENITAL WARTS
    ✓ 
    Drug product
  
  

See also...

• Veregen Consumer Information (Drugs.com)
• Veregen Consumer Information (Wolters Kluwer)
• Veregen topical Consumer Information (Cerner Multum)
• Veregen Advanced Consumer Information (Micromedex)
• Veregen AHFS DI Monographs (ASHP)
• Polyphenon E Consumer Information (Drugs.com)
• Sinecatechins Consumer Information (Wolters Kluwer)
• Kunecatechins topical Consumer Information (Cerner Multum)
• Sinecatechins topical Consumer Information (Cerner Multum)
• Sinecatechins Topical application Advanced Consumer Information (Micromedex)
• Sinecatechins AHFS DI Monographs (ASHP)